Value proposition
[Automatic translation follows] A new player committed to tackle #glioblastoma and #brain #cancer
Hemerion is a clinical stage HealthTech company. Its first breakthrough technology jointly designed with University of Lille, Inserm and University Hospital of Lille, addresses brain cancer and aims to help patients in their fight against glioblastoma.
Hemerion results of over 10 years of leading academic and clinical researches on innovative approaches to treat Glioblastoma.
Today, Hemerion owns a unique and disruptive technology, already evaluated in frontline approach to treat patients harboring brain cancer.Original language
A new player committed to tackle #glioblastoma and #brain #cancer
Hemerion is a clinical stage HealthTech company. Its first breakthrough technology jointly designed with University of Lille, Inserm and University Hospital of Lille, addresses brain cancer and aims to help patients in their fight against glioblastoma.
Hemerion results of over 10 years of leading academic and clinical researches on innovative approaches to treat Glioblastoma.
Today, Hemerion owns a unique and disruptive technology, already evaluated in frontline approach to treat patients harboring brain cancer.
Advancing cancer therapies. At the speed of light.
Advancing cancer therapies with Hemerion Therapeutics' innovative technology to fight brain cancer and glioblastoma.
https://hemerion.com/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 Eurasanté Startup accelerator & VC, Biotechnology, Biotechnology Research | Eurasanté Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 24 Mar 2025 | | |
 Business France National and local authorities, Government Administration | Business France National and local authorities, Government Administration | Other 29 May 2024 | | |